Efficacy of ezetimibe as monotherapy or combination therapy in hypercholesterolemic patients with and without diabetes

Journal of Medical Investigation

Volumn 58, Issue 1-2, 2011, Pages 86-94

  Kishimoto, Miyako ^a   Sugiyama, Takehiro ^a   Osame, Keiichiro ^a   Takarabe, Daisuke ^a   Okamoto, Masahide ^a   Noda, Mitsuhiko ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Cholesterol absorption; Cholesterol synthesis; Ezetimibe; Hypercholesterolemia

Indexed keywords

ANTIDIABETIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CAMPESTEROL; CHOLESTANOL; CHOLESTEROL; EZETIMIBE; FENOFIBRATE; GLUCOSE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; INSULIN; LATHOSTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SITOSTEROL;

ADD ON THERAPY; ADULT; AGE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIET THERAPY; DRUG EFFICACY; EXERCISE; FEMALE; GLUCOSE METABOLISM; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY DYSFUNCTION; LIPID BLOOD LEVEL; LIVER DYSFUNCTION; MALE; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 79951924395     PISSN: 13431420     EISSN: None     Source Type: Journal    
DOI: 10.2152/jmi.58.86     Document Type: Article

References (45)

1. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ: Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 44: 720-732, 2004
2. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell CJ, Roger V, Rumsfeld J, Sorlie P, Steinberger J, Thom T, Wasserthiel-Smoller S, Hong Y: American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115: e69-e171, 2007
3. Strandberg TE, Tilvis RS, Pitkala KH, Miettinen TA: Cholesterol and glucose metabolism and recurrent cardiovascular events among the elderly. A prospective Study. J Am Coll Cardiol 48: 708-714, 2006
4. Miettinen TA, Gylling H, Strandberg T, Sarna D: Baseline serum cholesterol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. BMJ 316: 1127-1130, 1988
5. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7-22, 2002
6. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM: Pravastatin or Atorvas-tatin Evaluation and Infection Therapy-Throm-bolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 35: 1495-1504, 2004
7. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352: 1425-1435, 2005
8. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J: Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myo-cardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294: 2437-2445, 2005
9. Armitage J: The safety of statins in clinical practice. Lancet 370: 1781-1790, 2007
10. Harris M., Davis W., Brown WV: Ezetimibe. Drugs of Today 39: 229-247, 2003
11. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB: Ezetimibe: a review of its metabolism, pharma-cokinetics and drug interactions. Clin Pharma-cokinet 44: 467-94, 2005
12. Davies JP, Levy B, Ioannou YA: Evidence for a Niemann-pick C (NPC) gene family: identification and characterization of NPC1L1. Genomics 65: 137-145, 2000
13. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP: Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303: 1201-1204, 2004
14. Davis HR Jr, Hoos LM, Tetzloff G, Maguire M, Zhu LJ, Graziano MP, Altmann SW: Deficiency of Niemann-Pick C1 Like 1 prevents atherosclerosis in ApoE - /- mice. Arterioscler Thromb Vasc Biol 27: 841-849, 2007
15. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP: Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 303: 1201-1204, 2004
16. Derosa G, D'Angelo A, Franzetti IG, Ragonesi PD, Gadaleta G, Scalise F, Ciccarelli L, Piccinni MN, Cicero AF: Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipi-demia and previously intolerant to standard statin treatment. J Clin Pharm Ther 34: 267-276, 2009
17. Daskalopoulou SS, Mikhailidis DP: Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Curr Med Res Opin 22: 511-528, 2006
18. Japan Atherosclerosis Society: Japan Atherosclerosis Society (JAS) guideline for prevention of atherosclerotic cardiovascular diseases. J Atheroscler Thromb 5-57, 2007
19. The Committee of Japan diabetes society on the diagnosis criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 1: 212-228, 2010
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985
21. Ezetimibe for the treatment of hypercholes-terolaemia: a systematic review and economic evaluation. Ara R, Tumur I, Pandor A, Duenas A, Williams R, Wilkinson A, Paisley S, Chilcott J: Ezetimibe for the treatment of hypercholes-terolaemia: a systematic review and economic evaluation. Health Technol Assess 12: 1-212, 2008
22. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP: Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvas-tatin in 628 patients with primary hypercholes-terolemia: a prospective, randomized, double-blind trial. Circulation 107: 2409-2415, 2003
23. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, Suresh R, Sun S, Veltri EP: Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 40: 2125-2134, 2002
24. Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB, for the Ezetibibe Study Group: Efficacy and safety of ezetimibe coadministered with smvastatin in patients with primary hyper-cholesterolemia: a randomized,double-blind, placebo-controlled trial. Mayo Clin Proc 79: 620-629, 2004
25. Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J: A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: The Ezetimibe Add-On to Statin for Effecticeness (EASE) trial. Mayo Clin Proc 80: 587-595, 2005
26. Hoenig MR, Rolfe BE, Campbell JH: Cho-lestanol: A serum marker to guide LDL cholesterol- lowering therapy. Atherosclerosis 184: 247-254, 2006
27. Sudhop T, Lütjohann D, Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I, von Bergmann K: Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 106: 1943-1948, 2002
28. Sasaki J, Iwashita M, Kono S: Statins: Beneficial or adverse for glucose metabolism. J Athe-roscler Thromb 13: 123-129, 2006
29. Her AY, Kim JY, Kang SM, Choi D, Jang Y, Chung N, Manabe I, Lee SH: Effects of ator-vastatin 20 mg, rosuvastatin 10 mg, and ator-vastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism. J Cardiovasc Pharmacol Ther 15: 167-174, 2010
30. Yamakawa T, Takano T, Tanaka S, Kadonosono K, Terauchi Y: Influence of putavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 15: 269-275, 2008
31. Takano T, Yamakawa T, Takahashi M, Kimura M, Okamura A. Influences of statins on glucose tolerance in patients with type 2 diabetes mel-litus. J Atheroscler Thromb 13: 95-100, 2006
32. Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T: Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycae-mic control. Diabetologia 49: 1881-1892, 2006
33. Ishikawa M, Okajima F, Inoue N, Motomura K, Kato T, Takahahsi A, Oikawa S, Yamada N, Shimano H: Distinct effects of pravastatin, atrovastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells. J Athe-roscler Thromb 13: 329-335, 2006
34. Hiramitsu S, Ishiguro Y, Matsuyama H, Yamada K, Kato K, Noba M, Uemura A, Yoshida S, Matsubara Y, Kani A, Hasegawa K, Hishida H, Ozaki Y: The effects of Ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia. J Atheroscler Thromb 17: 106-114, 2010
35. Tomkin GH: Ezetimibe-new anti-atherogenic properties? Br J Pharmacol 156: 1216-1217, 2009
36. Miettinen TA, Gylling H: Cholesterol absorption efficiency and sterol metabolism in obesity. Atherosclerosis 153: 241-248, 2000
37. Miettinen TA, Gylling H, Viikari J, Lehtimäki T, Raitakari OT: Synthesis and absorption of cholesterol in Finnish boys by serum non-cholesterol sterols. The cardiovascular risk in young Finns study. Atherosclerosis 200: 177-183, 2008
38. Chan DC, Watts GF, Barrett PH, O'Neill FH, Thompson GR: Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome. Obes Res 11: 591-596, 2003
39. Pihlajamäki J, Gylling H, Miettinen TA, Laakso M: Insulin resistance is associated with increased cholesterol synthesis and decreased cholesterol absorption in normoglycemic men. J Lipid Res 45: 507-512, 2004
40. Simonen PP, Gylling HK, Miettinen TA: Diabetes contributes to cholesterol metabolism regardless of obesity. Diabetes Care 25: 1511-1515, 2002
41. Mok HY, von Bergmann K, Grundy SM: Effects of continuous and intermittent feeding on biliary lipid outputs in man: application for measurements of intestinal absorption of cholesterol and bile acids. J Lipid Res 20: 389-398, 1979
42. Lally S, Tan CY, Owens D, Tomkin GH: Messenger RNA levels of genes involved in dys-regulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein. Diabetologia 49: 1008-1016, 2006
43. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E; ENHANCE Investigators: Simvasta-tin with or without Ezetimibe in Familial Hy-percholesterolemia. N Engl J Med 358: 1431-43, 2008
44. Pearson TA, Ballantyne CM, Veltri E, Shah A, Bird S, Lin J, Rosenberg E, Tershakovec AM: Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo - controlled trials of ezetimibe monother-apy or ezetimibe added to baseline statin therapy. Am J Cardiol 103: 369-374, 2009
45. Sager PT, Capece R, Lipka L, Strony J, Yang B, Suresh R, Mitchel Y, Veltri E: Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hyper-cholesterolemic patients. Atherosclerosis 179: 361-367, 2005